General company profile

AM-Pharma BV is a biopharmaceutical company developing recombinant Alkaline Phosphatase for clinical use.

AM-Pharma’s purpose is to save the lives of patients confronted with kidney disease, sepsis and organ injury. Our initial focus is sepsis-associated acute kidney injury, the cause of death for hundreds of thousands of people hospitalized each year. Our proprietary recombinant human alkaline phosphatase has the potential to become the first treatment specifically developed for sepsis-associated acute kidney injury and is now in a global pivotal Phase III clinical trial. We are a dedicated team driven to bring treatment options to severely ill patients, their families and acute care professionals.

Company activities:

AM-Pharma is developing a treatment for sepsis and acute kidney injury, that could be lifesaving

AM-Pharma, founded in 2001 and based in Utrecht, the Netherlands, has entered into late-stage clinical development for its treatment for sepsis-associated acute kidney injury (SA-AKI): recombinant human alkaline phosphatase therapeutic. The company is focused on the successful execution of its Phase III REVIVAL pivotal trial while continuing to build an organization committed to using its insight and knowledge for other kidney disease, sepsis and organ injury-related indications.

Company info

Stadsplateau 6
3521 AZ Utrecht
Active in sectors
Bio/Life Sciences
Type of organisation

Create a job alert

Would you like to receive the latest vacancies in your e-mail box? Create a job alert based on your keyword(s) and preferences.

Sign up

Hyphen Projects uses cookies to remember certain preferences and align interests.
By continuing to use this site, you consent to our use of cookies.